How mutations in a specific gene affect blood vessel function in Alzheimer's disease
Impairment of Ischemia-induced Vascular Functions by PS1 FAD Mutants
This study is looking at how changes in a specific gene related to familial Alzheimer's disease affect the brain's ability to create new blood vessels when blood flow is reduced, which could help us find new ways to support brain health for people with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11005030 on NIH RePORTER |
What this research studies
This research investigates how mutations in the Presenilin1 (PS1) gene, which are linked to familial Alzheimer's disease, impair the brain's ability to form new blood vessels in response to ischemia (reduced blood flow). The study focuses on the role of the EphB4/ephrinB2 system in regulating angiogenesis, which is crucial for maintaining healthy brain function. By examining the effects of PS1 FAD mutants on brain endothelial cells, the research aims to understand how these mutations contribute to neuronal damage and blood flow insufficiency in Alzheimer's patients. The findings could lead to new insights into potential therapeutic targets for improving vascular health in Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with Alzheimer's disease or exhibit symptoms related to Alzheimer's.
Not a fit: Patients who do not have Alzheimer's disease or related vascular issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance blood flow and reduce neuronal damage in Alzheimer's disease patients.
How similar studies have performed: Previous research has shown that targeting angiogenesis can be beneficial in other neurodegenerative conditions, suggesting potential for success in this area as well.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Georgakopoulos, Anastasios — Icahn School of Medicine at Mount Sinai
- Study coordinator: Georgakopoulos, Anastasios
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.